Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
- PMID: 30503797
- PMCID: PMC6326857
- DOI: 10.1016/j.sxmr.2018.09.006
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
Abstract
Introduction: Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM's chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs.
Aim: To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs.
Methods: A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included.
Main outcome measure: To complete a review of peer-reviewed literature.
Results: Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results.
Conclusion: SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84-94.
Keywords: Androgens; Drug-Related Side Effects and Adverse Reactions; Hypogonadism; Selective Androgen Receptor Modulators.
Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
Figures

Similar articles
-
Selective androgen receptor modulators: the future of androgen therapy?Transl Androl Urol. 2020 Mar;9(Suppl 2):S135-S148. doi: 10.21037/tau.2019.11.02. Transl Androl Urol. 2020. PMID: 32257854 Free PMC article. Review.
-
New selective estrogen and androgen receptor modulators.Curr Opin Rheumatol. 2009 Jul;21(4):374-9. doi: 10.1097/BOR.0b013e32832ca447. Curr Opin Rheumatol. 2009. PMID: 19412100 Free PMC article. Review.
-
Modulators of androgen and estrogen receptor activity.Crit Rev Eukaryot Gene Expr. 2010;20(4):275-94. doi: 10.1615/critreveukargeneexpr.v20.i4.10. Crit Rev Eukaryot Gene Expr. 2010. PMID: 21395502 Review.
-
Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51. doi: 10.1097/SPC.0000000000000015. Curr Opin Support Palliat Care. 2013. PMID: 24189892 Review.
-
Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review.Steroids. 2020 Dec;164:108753. doi: 10.1016/j.steroids.2020.108753. Epub 2020 Oct 24. Steroids. 2020. PMID: 33148520 Review.
Cited by
-
Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles.Int J Mol Sci. 2022 Apr 15;23(8):4404. doi: 10.3390/ijms23084404. Int J Mol Sci. 2022. PMID: 35457222 Free PMC article.
-
Androgen Receptor and Cardiovascular Disease: A Potential Risk for the Abuse of Supplements Containing Selective Androgen Receptor Modulators.Nutrients. 2023 Jul 26;15(15):3330. doi: 10.3390/nu15153330. Nutrients. 2023. PMID: 37571268 Free PMC article. Review.
-
Preclinical assessment of the selective androgen receptor modulator RAD140 to increase muscle mass and bone mineral density.Physiol Rep. 2025 Jul;13(14):e70463. doi: 10.14814/phy2.70463. Physiol Rep. 2025. PMID: 40680216 Free PMC article.
-
LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.Cureus. 2024 Sep 17;16(9):e69601. doi: 10.7759/cureus.69601. eCollection 2024 Sep. Cureus. 2024. PMID: 39421081 Free PMC article.
-
RAD-140 Drug-Induced Liver Injury.Ochsner J. 2022 Winter;22(4):361-365. doi: 10.31486/toj.22.0005. Ochsner J. 2022. PMID: 36561105 Free PMC article.
References
-
- Crawford J, Prado CMM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, et al. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep 2016;18:37. doi:10.1007/s11912-016-0522-0. - DOI - PMC - PubMed
-
- Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153–61. doi:10.1007/s13539-011-0034-6. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials